Janus Henderson Group PLC Has $101.60 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Janus Henderson Group PLC lowered its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,165,063 shares of the medical research company's stock after selling 438,117 shares during the period. Janus Henderson Group PLC owned approximately 4.80% of NeoGenomics worth $101,600,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of NeoGenomics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock valued at $234,673,000 after purchasing an additional 195,793 shares in the last quarter. Greenhouse Funds LLLP lifted its holdings in shares of NeoGenomics by 5.3% during the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock valued at $77,487,000 after purchasing an additional 237,491 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of NeoGenomics by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock valued at $56,645,000 after purchasing an additional 78,211 shares in the last quarter. First Light Asset Management LLC lifted its holdings in shares of NeoGenomics by 3.0% during the 4th quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company's stock valued at $52,202,000 after purchasing an additional 91,030 shares in the last quarter. Finally, Segall Bryant & Hamill LLC lifted its holdings in shares of NeoGenomics by 11.6% during the 4th quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company's stock valued at $34,836,000 after purchasing an additional 220,415 shares in the last quarter. Institutional investors own 98.50% of the company's stock.

Insiders Place Their Bets

In other news, Director David Brian Perez bought 10,000 shares of the company's stock in a transaction dated Monday, May 5th. The stock was bought at an average price of $7.63 per share, with a total value of $76,300.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company's stock, valued at $76,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Warren Stone bought 5,700 shares of the company's stock in a transaction dated Monday, May 12th. The shares were purchased at an average cost of $8.58 per share, with a total value of $48,906.00. Following the acquisition, the chief operating officer now directly owns 108,280 shares of the company's stock, valued at approximately $929,042.40. This represents a 5.56% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 65,600 shares of company stock valued at $512,438 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

NeoGenomics Stock Up 3.4%

Shares of NASDAQ:NEO traded up $0.27 during midday trading on Friday, hitting $8.11. The stock had a trading volume of 1,257,184 shares, compared to its average volume of 1,127,511. NeoGenomics, Inc. has a 12 month low of $6.08 and a 12 month high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The business's 50-day simple moving average is $9.01 and its 200-day simple moving average is $12.89. The company has a market cap of $1.04 billion, a P/E ratio of -13.08 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $168.04 million for the quarter, compared to the consensus estimate of $171.38 million. During the same period last year, the firm earned ($0.02) earnings per share. The company's revenue for the quarter was up 7.6% compared to the same quarter last year. On average, sell-side analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NEO has been the topic of a number of recent research reports. Leerink Partners downgraded shares of NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $25.00 to $9.00 in a report on Wednesday, April 30th. Guggenheim initiated coverage on shares of NeoGenomics in a report on Thursday. They issued a "neutral" rating on the stock. The Goldman Sachs Group lowered their price objective on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Needham & Company LLC lowered their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Finally, Piper Sandler set a $12.00 price objective on shares of NeoGenomics and gave the company an "overweight" rating in a report on Tuesday, May 6th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, NeoGenomics has a consensus rating of "Hold" and a consensus target price of $13.83.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.